258 related articles for article (PubMed ID: 23797604)
21. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
[TBL] [Abstract][Full Text] [Related]
22. Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.
Dore DD; Trivedi AN; Mor V; Lapane KL
Pharmacotherapy; 2009 Jul; 29(7):775-83. PubMed ID: 19558251
[TBL] [Abstract][Full Text] [Related]
23. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
[TBL] [Abstract][Full Text] [Related]
24. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
25. Rosiglitazone is not associated with an increased risk of bladder cancer.
Tseng CH
Cancer Epidemiol; 2013 Aug; 37(4):385-9. PubMed ID: 23619142
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM
PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036
[TBL] [Abstract][Full Text] [Related]
27. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Tseng CH
J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
[TBL] [Abstract][Full Text] [Related]
29. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
30. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
31. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.
Hsu JC; Cheng CL; Ross-Degnan D; Wagner AK; Zhang F; Kao Yang YH; Liu LL; Tai HY; Chen KH; Yang PW; Lu CY
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1026-35. PubMed ID: 26251229
[TBL] [Abstract][Full Text] [Related]
32. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.
Koro CE; Fu Q; Stender M
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):989-96. PubMed ID: 18759378
[TBL] [Abstract][Full Text] [Related]
33. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
34. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.
Jin SM; Song SO; Jung CH; Chang JS; Suh S; Kang SM; Jung I; Park CY; Kim JH; Cho JH; Lee BW
J Korean Med Sci; 2014 Feb; 29(2):238-42. PubMed ID: 24550651
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence.
Davidson MB
J Diabetes Complications; 2016 Aug; 30(6):981-5. PubMed ID: 27133452
[TBL] [Abstract][Full Text] [Related]
36. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
Colhoun HM; Livingstone SJ; Looker HC; Morris AD; Wild SH; Lindsay RS; Reed C; Donnan PT; Guthrie B; Leese GP; McKnight J; Pearson DW; Pearson E; Petrie JR; Philip S; Sattar N; Sullivan FM; McKeigue P;
Diabetologia; 2012 Nov; 55(11):2929-37. PubMed ID: 22945303
[TBL] [Abstract][Full Text] [Related]
37. Pioglitazone and bladder cancer: a propensity score matched cohort study.
Wei L; MacDonald TM; Mackenzie IS
Br J Clin Pharmacol; 2013 Jan; 75(1):254-9. PubMed ID: 22574756
[TBL] [Abstract][Full Text] [Related]
38. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
Tseng CH
Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
[TBL] [Abstract][Full Text] [Related]
39. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
40. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
